STGN Stratagene Corp (MM)

Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostics products, announced today that VWR International, Inc. will become a distributor of Stratagene�s full line of research products in Canada. The companies expect that customers will be able to access Stratagene products through VWR beginning in October 2006. Under the terms of the agreement, Stratagene and VWR will service Canadian customers in an integrated manner. In addition to increasing Stratagene�s presence in the Canadian market with broader sales representation and customer relationships, VWR will inventory Stratagene products in warehouses located in Edmonton and Mississauga to provide Canadian customers with faster and more economical delivery. Stratagene will continue to support Canadian customers with direct sales representation and field applications support personnel in Canada as well as provide technical support and instrument service from its U.S. offices. �Both of our companies possess strengths which we want to leverage to provide the best life science research products and support to our mutual Canadian customers,� said Joseph A. Sorge, MD, President and CEO of Stratagene. �Stratagene is recognized as a premier brand name in life sciences and is a leader in many product areas, while VWR provides well-established, reputable distribution and coverage of the Canadian market. Together, we believe we offer Canadian customers unparalleled combination of value.� "This agreement significantly enhances VWR's network of supplier partnerships by extending Stratagene�s industry-leading life science research products to our customers," said Brian Kerslake, VWR Vice President of Life Science. "Our relationship will continue to strengthen VWR's ability to provide our customers with superior solutions and technology." About Stratagene Corporation Stratagene is a developer, manufacturer and marketer of specialized life science research and diagnostic products. The Company's life science research unit supports advances in science by inventing, manufacturing and distributing products that simplify, accelerate and improve research. These products are used throughout the academic, industrial and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. The Company's diagnostic unit develops and manufactures products for urinalysis as well as high quality automated instrument and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders. In addition, by combining its expertise in diagnostics and molecular biology, as well as its experience with FDA regulatory procedures, the Company is pursuing opportunities to expand its product portfolio to include molecular diagnostic kits and instrumentation. More information is available at www.stratagene.com. About VWR International, Inc. VWR International is a leader in the global research laboratory industry with worldwide sales in excess of $3.1 billion US dollars. VWR's business is highly diversified across a spectrum of products and services, customer groups and geography. The company offers more than 1,200,000 products, from more than 2,500 manufacturers, to over 250,000 customers throughout North America and Europe. VWR's primary customers work in the pharmaceutical, life science, chemical, technology, food processing and consumer product industries. Other important customers include universities and research institutes; governmental agencies; environmental testing organizations; and primary and secondary schools. VWR International affiliates operate in 20 countries and employ approximately 6,100 people. The company's mission is to deliver excellence in the distribution of scientific supplies. The VWR International Group is headquartered in West Chester, Pennsylvania. For more information on VWR International or a copy of this release, phone (610) 430-7258 or visit www.vwr.com, or write, VWR International, Inc., 1310 Goshen Parkway, P.O. Box 2656, West Chester, PA 19380-0906. VWR and design are trademarks of VWR International, Inc. Safe Harbor Statement Certain statements in this news release that are not historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements. Stratagene generally identifies forward-looking statements by using words like "believe," "intend," "target," "expect," "estimate," "may," "should," "plan," "project," "contemplate," "anticipate," "predict" or similar expressions. You can also identify forward-looking statements by discussions of strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results of Stratagene to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Among the important factors that could cause actual results to differ materially from those contained in or implied by the forward-looking statements are risks associated with the company's inability to sufficiently anticipate market needs and develop products and product enhancements that achieve market acceptance, the company's ability to compete effectively in the diagnostics and life science research markets, variability of the company's quarterly revenues and operating results, the failure of the company to retain key employees, the company's ability to obtain additional debt or equity financing, the possibility of declining sales due in part to a reduction in research and development budgets or government funding, the company's ongoing ability to protect its own intellectual property rights and to avoid violating the intellectual property rights of third parties, extended manufacturing difficulties and currency fluctuations. For more information about these and other factors that could cause actual results to differ materially from those contained in or implied by the forward-looking statements please see Item �1A. Risk Factors" included in Stratagene's Annual Report on Form 10-K for the year ended December 31, 2005 and in other reports filed by Stratagene from time to time with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q. Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostics products, announced today that VWR International, Inc. will become a distributor of Stratagene's full line of research products in Canada. The companies expect that customers will be able to access Stratagene products through VWR beginning in October 2006. Under the terms of the agreement, Stratagene and VWR will service Canadian customers in an integrated manner. In addition to increasing Stratagene's presence in the Canadian market with broader sales representation and customer relationships, VWR will inventory Stratagene products in warehouses located in Edmonton and Mississauga to provide Canadian customers with faster and more economical delivery. Stratagene will continue to support Canadian customers with direct sales representation and field applications support personnel in Canada as well as provide technical support and instrument service from its U.S. offices. "Both of our companies possess strengths which we want to leverage to provide the best life science research products and support to our mutual Canadian customers," said Joseph A. Sorge, MD, President and CEO of Stratagene. "Stratagene is recognized as a premier brand name in life sciences and is a leader in many product areas, while VWR provides well-established, reputable distribution and coverage of the Canadian market. Together, we believe we offer Canadian customers unparalleled combination of value." "This agreement significantly enhances VWR's network of supplier partnerships by extending Stratagene's industry-leading life science research products to our customers," said Brian Kerslake, VWR Vice President of Life Science. "Our relationship will continue to strengthen VWR's ability to provide our customers with superior solutions and technology." About Stratagene Corporation Stratagene is a developer, manufacturer and marketer of specialized life science research and diagnostic products. The Company's life science research unit supports advances in science by inventing, manufacturing and distributing products that simplify, accelerate and improve research. These products are used throughout the academic, industrial and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. The Company's diagnostic unit develops and manufactures products for urinalysis as well as high quality automated instrument and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders. In addition, by combining its expertise in diagnostics and molecular biology, as well as its experience with FDA regulatory procedures, the Company is pursuing opportunities to expand its product portfolio to include molecular diagnostic kits and instrumentation. More information is available at www.stratagene.com. About VWR International, Inc. VWR International is a leader in the global research laboratory industry with worldwide sales in excess of $3.1 billion US dollars. VWR's business is highly diversified across a spectrum of products and services, customer groups and geography. The company offers more than 1,200,000 products, from more than 2,500 manufacturers, to over 250,000 customers throughout North America and Europe. VWR's primary customers work in the pharmaceutical, life science, chemical, technology, food processing and consumer product industries. Other important customers include universities and research institutes; governmental agencies; environmental testing organizations; and primary and secondary schools. VWR International affiliates operate in 20 countries and employ approximately 6,100 people. The company's mission is to deliver excellence in the distribution of scientific supplies. The VWR International Group is headquartered in West Chester, Pennsylvania. For more information on VWR International or a copy of this release, phone (610) 430-7258 or visit www.vwr.com, or write, VWR International, Inc., 1310 Goshen Parkway, P.O. Box 2656, West Chester, PA 19380-0906. VWR and design are trademarks of VWR International, Inc. Safe Harbor Statement Certain statements in this news release that are not historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements. Stratagene generally identifies forward-looking statements by using words like "believe," "intend," "target," "expect," "estimate," "may," "should," "plan," "project," "contemplate," "anticipate," "predict" or similar expressions. You can also identify forward-looking statements by discussions of strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results of Stratagene to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Among the important factors that could cause actual results to differ materially from those contained in or implied by the forward-looking statements are risks associated with the company's inability to sufficiently anticipate market needs and develop products and product enhancements that achieve market acceptance, the company's ability to compete effectively in the diagnostics and life science research markets, variability of the company's quarterly revenues and operating results, the failure of the company to retain key employees, the company's ability to obtain additional debt or equity financing, the possibility of declining sales due in part to a reduction in research and development budgets or government funding, the company's ongoing ability to protect its own intellectual property rights and to avoid violating the intellectual property rights of third parties, extended manufacturing difficulties and currency fluctuations. For more information about these and other factors that could cause actual results to differ materially from those contained in or implied by the forward-looking statements please see Item "1A. Risk Factors" included in Stratagene's Annual Report on Form 10-K for the year ended December 31, 2005 and in other reports filed by Stratagene from time to time with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q.